49B Panoramica delle azioni BeiGene, Ltd., una società di oncologia, è impegnata nella scoperta e nello sviluppo di vari trattamenti per i pazienti affetti da cancro negli Stati Uniti, in Cina, in Europa e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
BeiGene, Ltd. Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per BeiGene Prezzi storici delle azioni Prezzo attuale dell'azione US$12.50 Massimo di 52 settimane US$17.30 Minimo di 52 settimane US$8.90 Beta 0.60 Variazione di 1 mese -8.09% Variazione a 3 mesi -9.42% Variazione di 1 anno 5.93% Variazione a 3 anni -28.86% Variazione a 5 anni 9.65% Variazione dall'IPO 13.12%
Notizie e aggiornamenti recenti
BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets Dec 10
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer Nov 27
BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee Oct 28
BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024 Sep 30 BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024 Sep 26
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy Sep 17 Vedi altri aggiornamenti
BeiGene, Ltd. Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA and Novel Pipeline Assets Dec 10
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer Nov 27
BeiGene, Ltd. Announces Passing Away of Donald Glazer, A Board Member and the Chair of the Nominating and Corporate Governance Committee Oct 28
BeiGene, Ltd. to Report Q3, 2024 Results on Nov 13, 2024 Sep 30 BeiGene, Ltd. Appoints Shalini Sharp to Board of Directors and Member of the Audit Committee, Effective September 27, 2024 Sep 26
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy Sep 17
BeiGene, Ltd. to Report Q2, 2024 Results on Aug 07, 2024 Jul 24
Beigene, Ltd. Appoints Aaron Rosenberg as the Principal Financial Officer, Effective from July 22, 2024 Jul 19
BeiGene, Ltd. Announces CFO Changes Jul 18
BeiGene, Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Jun 28 BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL May 25
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 May 16
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer Apr 23
BeiGene, Ltd., Annual General Meeting, Jun 05, 2024 Apr 17
BeiGene, Ltd. to Report Q1, 2024 Results on May 11, 2024 Mar 29
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy Mar 15
BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma Mar 08
BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 Mar 06
BeiGene, Ltd. Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer Feb 28
BeiGene, Ltd. Announces Adults Living with Chronic Lymphocytic Leukemia in Ontario and Quebec Now Have Access, Through Public Reimbursement, to BRUKINSA® (Zanubrutinib) Jan 31
Beigene, Ltd. Announces Board Changes Jan 23
BeiGene, Ltd. Announces FDA Approves Label Update for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia Dec 22
BeiGene, Ltd. Receives European Commission Approval for BRUKINSA®? (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma Nov 18
Beigene, Ltd. Receives Positive Recommendation from Nice in U.K. for Adult Patients with Chronic Lymphocytic Leukemia Oct 21
BeiGene, Ltd. Presentations at ESMO 2023 Demonstrate Robust Clinical Strategy for Tislelizumab as Monotherapy and in Combination with Pipeli Oct 17
BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma Oct 15
BeiGene Receives Positive CHMP Opinion for BRUKINSA®? (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma Oct 14
U.S. FDA Accepts Biologics License Application in First-Line Advanced ESCC Sep 22
BeiGene, Ltd. Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA(R) Sep 20
Beigene, Ltd. Announces Change of Chair of Audit Committee Sep 15
Beigene Announces Positive CHMP Opinion for Tislelizumab as Treatment for Advanced or Metastatic ESCC Jul 23
Beigene, Ltd. Announces FDA Acceptance of sNDA for Fifth Brukinsa(R) Indication Jul 13
BeiGene, Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Jun 28 BeiGene Highlights Significant Brukinsa® (Zanubrutinib) Data at 17th International Conference on Malignant Lymphoma
Pharmacyclics LLC Files Complaint Against Beigene, Ltd. and Beigene USA, Inc Jun 16
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress Jun 10
BeiGene, Ltd. Announces Approval of BRUKINSA (Zanubrutinib) by Health Canada for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia May 31
BeiGene, Ltd. Announces Presentations At the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio May 26
Beigene, Ltd. Provides Update Regarding Recent Business Developments May 09
BeiGene Announces BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia Jan 21
Brukinsa (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma in Great Britain by MHRA Jan 20 BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List Jan 19
BeiGene, Ltd. Announces Center for Drug Evaluation of the China National Medical Products Administration Accepts Supplemental Biologics License Application Jan 07 BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab Dec 31
Beigene, Ltd.'S Brukinsa Demonstrated Superior Progression-Free Survival over Imbruvica (Ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker At ASH Dec 14
Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for Brukinsa® Versus Imbruvica® in Late-Breaking Oral Session At Ash 2022 Nov 23
Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee Nov 22
BeiGene Receives European Commission Approval for Brukinsa® (Zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (Cll) Nov 18
Beigene, Ltd. Announces Brazil Approvals for Brukinsa® as A Treatment for Rare Blood Cancers Nov 11
Abbisko Therapeutics Co., Ltd. Completes First Patient Enrollment in Phase II Clinical Trial for Investigational Pan-FGFR Inhibitor ABSK091 in Combination with Anti-PD-1 Antibody Tislelizumab Developed by BeiGene, Ltd. in Urothelial Carcinoma Nov 05
BeiGene Receives European Commission Approval for BRUKINSA(R) (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma Nov 03
BeiGene, Ltd. Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America Oct 27
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL Oct 15
Beigene Announces Positive Topline Results from Final Progression-Free Survival Analysis of Brukinsa® (Zanubrutinib) Compared to Imbruvica® (Ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (Cll) Trial Oct 13 NICE Recommends Beigene’s BRUKINSA® (Zanubrutinib) for Patients with Waldenström’s Macroglobulinemia Who Have Had At Least One Treatment
Beigene, Ltd. Announces Appointment of Member of Compensation Committee Sep 15
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer Sep 10
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China Aug 24
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer Aug 10
Beigene Provides Regulatory Update on the U.S. Biologics License Application (Bla) for Pd 1 Inhibitor Tislelizumab in 2L Escc Jul 15
BeiGene, Ltd. Appoints Chan Lee as General Counsel, July 18 2022 Jul 14
Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer Jul 13
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma Jul 01
Beigene, Ltd. Announces Executive Changes Jun 23
Beigene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab Jun 22 Ministry of Health in Kuwait Approves Beigene, Ltd.'s BRUKINSA™ (Zanubrutinib) in 50 Markets
BeiGene, Ltd. Announces NMPA Grants its Anti-PD-1 Antibody Tislelizumab Approval for First-Line Treatment of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer and Conditional Approval for Treatment of Patients with Hepatocellular Carcinoma Jun 11
Beigene Announces the Approval in China of BLINCYTO® for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia May 05
BeiGene, Ltd., Annual General Meeting, Jun 22, 2022 May 02
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting Apr 28
BeiGene, Ltd. to Report Q1, 2022 Results on May 05, 2022 Apr 22
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series Apr 20
BeiGene, Ltd. Announces China National Medical Products Administration Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma Apr 16
Beigene Announces IRC Determines Brukinsa® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia Apr 12
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022 Apr 09
Beigene, Ltd. Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC Apr 07 BeiGene, Ltd. Announces Resignation of Jane Huang, Chief Medical Officer
BeiGene, Ltd. Announces Appointment of Margaret Han Dugan as Member of the Commercial and Medical Affairs Advisory Committee of its Board of Directors Mar 01
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia Feb 24
Beigene, Ltd. Announces Approval for Brukinsa (Zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia Feb 18 BeiGene, Ltd. to Report Fiscal Year 2021 Final Results on Mar 31, 2022 BeiGene, Ltd. Announces Executive Changes Feb 05
BeiGene, Ltd. Announces Management Changes Feb 03
BeiGene, Ltd. Announces Board Appointments Feb 02
BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation Jan 30
BeiGene, Ltd. Announces Positive Findings from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy in First-Line Gastric or Gastroesophageal Junction Cancer Jan 25
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Waldenström’s Macroglobulinemia Jan 22 Rendimenti per gli azionisti 49B DE Biotechs DE Mercato 7D 0.8% -3.5% -2.0% 1Y 5.9% -14.7% 6.9%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: 49B ha superato il German Biotechs che ha restituito -14.7 % nell'ultimo anno.
Rendimento vs Mercato: 49B ha eguagliato il mercato German che ha restituito 6.9 % nell'ultimo anno.
Volatilità dei prezzi Is 49B's price volatile compared to industry and market? 49B volatility 49B Average Weekly Movement 7.5% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Il prezzo delle azioni di 49B è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di 49B è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2010 10,000 John Oyler www.beigene.com
BeiGene, Ltd., un'azienda oncologica, è impegnata nella scoperta e nello sviluppo di vari trattamenti per i pazienti affetti da cancro negli Stati Uniti, in Cina, in Europa e a livello internazionale. I suoi prodotti in fase commerciale comprendono BRUKINSA, un inibitore a piccole molecole della tirosina chinasi di Bruton (BTK) per il trattamento di vari tumori del sangue; TEVIMBRA, un'immunoterapia a base di anticorpi anti-PD-1 per il trattamento di vari tumori solidi e del sangue; e PARTRUVIX, un inibitore selettivo a piccole molecole degli enzimi PARP1 e PARP2, in fase di valutazione come monoterapia e in combinazione per il trattamento di vari tumori solidi. I prodotti in fase clinica dell'azienda comprendono BGB-11417, un piccolo inibitore molecolare di Bcl-2; BGB-16673, un composto chimerico di attivazione della degradazione mirato a BTK e attivo contro BTK wild-type e mutante; BGB-10188; BGB-21447, un inibitore di Bcl-2; Ociperlimab (BGB-A1217), un inibitore di TIGIT; Zanidatamab, un anticorpo bispecifico mirato a HER2; Surzebiclimab (BGB-A425), un inibitore di TIM-3; BGB-A445, un anticorpo agonista di OX40; BGB-15025, un piccolo inibitore di HPK1; BGB-24714, un mimetico di SMAC; BGB-26808, un inibitore di HPK-1; Lifirafenib e BGB-3245, che sono inibitori di RAF; BGB-30813; BGB-A3055, un anticorpo anti-CCR8; e BGB-43395, un inibitore di CDK-4.
Mostra di più BeiGene, Ltd. Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di BeiGene con la sua capitalizzazione di mercato? 49B statistiche fondamentali Capitalizzazione di mercato €17.97b Guadagni(TTM ) -€787.27m Ricavi(TTM ) €3.09b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) 49B Conto economico (TTM ) Ricavi CN¥23.51b Costo del fatturato CN¥3.84b Profitto lordo CN¥19.67b Altre spese CN¥25.66b Guadagni -CN¥5.99b
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -56.41 Margine lordo 83.67% Margine di profitto netto -25.50% Rapporto debito/patrimonio netto 29.6%
Come si è comportato 49B nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/23 05:38 Prezzo dell'azione a fine giornata 2024/12/20 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche BeiGene, Ltd. è coperta da 56 analisti. 29 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Brian Skorney Baird Michael Meng BOCI Research Ltd. Yonglin Yan BOCI Research Ltd.
Mostra 53 altri analisti 
